SMARCA4 and uveal melanoma: In addition, a BRG1 inhibitor, FHD-286 is currently in Phase 1 clinical trials for treating metastatic uveal melanoma and advanced hematologic malignancies50,51, highlighting the importance of BRG1 inhibition in cancer progression and metastasis.